Would you consider off label use of olaparib maintenance in patients with somatic BRCA1 mutated pancreatic adenocarcinoma?  

In addition to the comments above, it is worth observing that preliminary prospective data addressing this question was presented at AACR this year by @Kim Reiss Binder. Her group is evaluating the role of rucaparib maintenance for patients with either germline or somatic BRCA or PALB2 mutation...

I have been using olaparib as an off-label maintenance strategy for patients with germline mutations in dsDNA repair proteins. And, as a side-note, we have an ongoing trial at DFCI for niraparib for patients with germline or somatic alterations in dsDNA repair genes that extend beyond just BRCA1/2.T...

Definitely yes. However, it is infrequent to find a situation where one would stop FOLFIRINOX if the patient continues to respond. More likely, would use in situation where a patient would require a treatment break because of toxicity. Previously, would increase interval between treatments.